Colait and Myomo co-sponsor stroke research initiative

Colait and Myomo are launching a research collaboration to better understand unmet needs for people living with chronic stroke-related upper limb paralysis. The study will examine clinician perspectives and reimbursement barriers that affect access to care and rehabilitation technologies.

Why it matters: - Chronic stroke-related upper limb paralysis remains an unmet need in neurorehabilitation. - The research could help clarify barriers that affect care delivery, access and rehabilitation technology adoption. - Findings may inform how clinicians, providers and healthcare systems approach stroke recovery.

What happened: - Colait announced a collaboration with Myomo to co-sponsor a research initiative on June 11, 2026. - The study will focus on people living with chronic stroke-related upper limb paralysis. - Colait is powering the initiative with its AI-driven insight platform. - Myomo and Colait aim to identify and better understand unmet needs across the chronic stroke journey.

The details: - The study will explore changing perspectives of healthcare professionals. - The research will examine the reimbursement landscape that shapes access to care and rehabilitation technologies. - The initiative is intended to generate real-world insights into clinical, functional and systemic challenges. - The study is expected to include qualitative input from clinicians, including rehabilitation specialists and allied health professionals. - The research is meant to help inform future approaches to care delivery, access and innovation in stroke recovery. - Harry Kovelman, MD, Myomo’s chief medical officer, said chronic stroke remains one of the largest areas of unmet need in neurorehabilitation. - Kovelman said the collaboration combines Myomo’s advanced mobility solutions with Colait’s ability to surface actionable human insights at scale.

Between the lines: - The collaboration points to growing interest in pairing medical-device expertise with AI-driven qualitative research. - Reimbursement remains a key gatekeeper for rehabilitation access, so studying that system could be as important as studying clinical need. - The focus on clinician perspectives suggests the initiative is aimed at shaping both evidence generation and future commercial or care pathways.

What’s next: - Colait and Myomo expect the study to produce insights that can guide future care and innovation strategies. - The companies have not disclosed a timeline for publication or additional study milestones. - Colait says it embeds validated agents into workflows for pharmaceutical, biotech and medtech organizations. More information